CatalystMarker
← board

ALVOW

distress 4/10 · elevated risk
$0.18-44%today-49% from 52w high
alvotech.com1,279 employeesFounded 2013Luxembourg, Luxembourg
Revenue
$106M
Liquidity
$68M
Runway
1.4 yrs
Shares 1y
0%

Price & events

-38.4% over 6M
$0.17$0.27$0.37Mar 26May 26Jul 26912dilution: 424B5 offering (2026-06-16)dilution: FWP offering (2026-06-16)dilution: FWP offering (2026-06-15)dilution: 424B5 offering (2026-06-15)
CatalystRating changeDilutionFinancingdashed = today
-44.0%
1D
+5.9%
1W
-44.0%
1M
-44.0%
3M
—
6M
—
1Y
—
2Y
—
5Y
-38.4%
All

Overview

Market Cap
$57.72M
Enterprise Value
$1.26B
Volume
400
52 Week Range
$0.17 – $0.37
Total Shares
312.02M
Float Shares
123.17M
RVOL
7.94x
Beta
0.19

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (2)

  • SELARSDIUSTEKINUMAB-AEKN2024 · Prescription
  • SIMLANDIADALIMUMAB-RYVK2024 · Prescription

Capital structure — dilution & financing

Shares out: 312,021,375 · 4 offerings/1y · 0 PIPEs
  • 2026-06-16FWPoffering
  • 2026-06-16424B5offering
  • 2026-06-15424B5offering
  • 2026-06-15FWPoffering
  • 2024-11-06SC 13G/Astrategic_stake
  • 2024-08-29424B3offering
  • 2024-08-29EFFECTshelf_effective
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.